• A phase 2 clinical study to evaluate the efficacy and safety of bofanglutide injection and semaglutide (Ozempic^®) injection in adult Chinese patients with T2DM

• A phase 2 clinical study comparing the efficacy and safety of once-weekly GZR4 injection versus once-daily insulin Degludec injection in Chinese adult T2DM patients inadequately controlled on oral antidiabetic drug (OAD) therapy or OAD therapy in combination with basal insulin

The 61st EASD (European Association for the Study of Diabetes) Annual Meeting will take place as a hybrid event from 15 to 19 September 2025, providing the option to attend in person in Vienna, Austria or online via the Virtual Meeting platform. As Europe's largest and one of the most influential diabetes conference, the EASD Annual Meeting provides a premier global platform for researchers and healthcare professionals to share groundbreaking basic research, cutting-edge clinical trial results and engage in-depth expert discussions¹.

Two phase 2 clinical studies evaluating Gan & Lee Pharmaceuticals' bi-weekly GLP-1 receptor agonist (GLP-1 RA) bofanglutide (GZR18) injection and once-weekly basal insulin GZR4 injection have been accepted as oral presentations at EASD 2025.

Bi-weekly GLP-1 RA: bofanglutide (GZR18) injection

Abstract Number/ Title: 828 Efficacy and Safety of Bofanglutide (GZR18), a Bi-weekly GLP-1 RA, Compared to Semaglutide in Chinese Patients with T2D

Session Title: SO 073 The GLP-1 portfolio: diverse formulations for expanding clinical applications

Presentation Form: Short Oral Discussions

Session Time: 16 September 2025, 12:00 - 13:00 CEST

Presenter: Prof. Helena W. Rodbard | Endocrine and Metabolic Consultants, USA

Once-weekly basal insulin: GZR4 injection

Abstract Number/ Title: 185 Superior Glycemic Control Achieved with Once-Weekly Insulin GZR4 Compared to Once-Daily Insulin Degludec in Insulin-treated Chinese Subjects with T2D

Session Title: OP 31 Once weekly on weekend or weekday?

Presentation Form: Oral Presentations

Session Time: 18 September 2025, 15:30 - 17:00 CEST

Presenter: Prof. Liming Chen | Tianjin Medical University Chu Hsien-I Memorial Hospital, China

Abstract Number/ Title: 186 Comparable Glycemic Control of Once-Weekly Insulin GZR4 Relative to Once-Daily Insulin Degludec in Insulin-naïve Chinese Subjects with T2D

Session Title: OP 31 Once weekly on weekend or weekday?

Presentation Form: Oral Presentations

Session Time: 18 September 2025, 15:30 - 17:00 CEST

Presenter: Prof. Hans de Vries | Profil, German

Reference:

1. 61st EASD Annual Meeting. https://www.easd.org

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.